Subscribe to our free daily newsletters
. 24/7 Space News .




Subscribe to our free daily newsletters



Nanobodies Herald A New Era In Cancer Therapy

maybe this is the space age without the vacuum
Brussels (SPX) May 13, 2004
The vast majority of the current medicines for treating tumors - the so-called chemotherapeutics - are seldom specific. Indeed, because a chemotherapy treatment is not only toxic to cancer cells but to the body's normal cells as well, patients often experience severe side effects.

The VIB research team under the direction of Hilde Revets and Patrick De Baetselier (Department of Molecular and Cellular Interactions, Free University of Brussels) is searching - successfully - for new, specific, effective cancer therapies.

For several years now, the leading strategy in the treatment of cancer has been based on the production of antibodies, which are protective substances produced in the organism to defend against intruding foreign bodies - protecting us against infections arising from bacteria and viruses.

Antibodies can also react with tumor-specific substances that appear only on the cancer cell membrane. These ingenious antibodies seek out and bind very specifically to the cancer cells. As a result, the tumor is removed in a highly targeted, specific manner. At the moment, ten such medicines are available to patients.

But even though these antibody medicines are a good step in the right direction, there is clearly room for improvement. The antibodies that are being used are large proteins that have difficulty penetrating tumors. In addition, their complex structure makes large-scale production very difficult and expensive.

In order to cope with these problems, the VIB researchers are using camel antibodies. Extremely small compared to conventional antibodies, this unique class of antibodies has been renamed 'nanobodies'. Having all the advantages of the conventional antibodies, nanobodies also have several more important characteristics: they are small and they keep their tumor-specific character.

At the same time, they are very stable, soluble proteins that are much easier and less expensive to produce than conventional antibodies. So, researchers have recently begun to evaluate nanobodies as anti-cancer medicines. The first results look promising: in experiments conducted on mice, a tumor with a certain protein on its membrane was successfully counteracted through administration of a nanobody directed against this protein.

To translate these results into a possible application for humans, VIB is collaborating with Ablynx, a company established by VIB and GIMV in 2001 with the aim of marketing the nanobody technology. Today, Ablynx has already developed nanobodies against 16 different therapeutic targets that represent a wide range of diseases in humans. Two of these nanobodies are in the pre-clinical phase and, according to plan, will be ready to be clinically tested next year.

These recent results are a new step toward the development of medicines based on nanobodies. In addition to cancer, other life-threatening diseases - such as certain inflammatory diseases, or heart and vascular diseases - are possibly eligible for a medical treatment with nanobodies.

Related Links
Flanders Interuniversity Institute of Biotechnology
SpaceDaily
Search SpaceDaily
Subscribe To SpaceDaily Express

Telemedicine Cares For People In Remote Regions And Space
Huntsville AL (SPX) May 07, 2004
What do villages in the Amazon jungles, the peaks of Mount Everest and Mars have in common? All are remote places where doctors may not be available to provide medical care for patients.



Thanks for being here;
We need your help. The SpaceDaily news network continues to grow but revenues have never been harder to maintain.

With the rise of Ad Blockers, and Facebook - our traditional revenue sources via quality network advertising continues to decline. And unlike so many other news sites, we don't have a paywall - with those annoying usernames and passwords.

Our news coverage takes time and effort to publish 365 days a year.

If you find our news sites informative and useful then please consider becoming a regular supporter or for now make a one off contribution.

SpaceDaily Contributor
$5 Billed Once


credit card or paypal
SpaceDaily Monthly Supporter
$5 Billed Monthly


paypal only






Memory Foam Mattress Review
Newsletters :: SpaceDaily :: SpaceWar :: TerraDaily :: Energy Daily
XML Feeds :: Space News :: Earth News :: War News :: Solar Energy News








The content herein, unless otherwise known to be public domain, are Copyright 1995-2016 - Space Media Network. All websites are published in Australia and are solely subject to Australian law and governed by Fair Use principals for news reporting and research purposes. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA news reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. Privacy Statement All images and articles appearing on Space Media Network have been edited or digitally altered in some way. Any requests to remove copyright material will be acted upon in a timely and appropriate manner. Any attempt to extort money from Space Media Network will be ignored and reported to Australian Law Enforcement Agencies as a potential case of financial fraud involving the use of a telephonic carriage device or postal service.